Hormonal
GLP-1 receptor agonists and DPP-4 inhibitors provide effective glucose lowering with weight loss (GLP-1) or weight neutrality (DPP-4) and minimal hypoglycemia risk, outweighing potential risks of pancreatitis or thyroid cancer which lack convincing human evidence.
For patients with Type 2 Diabetes, GLP-1 receptor agonists (like liraglutide or exenatide) and DPP-4 inhibitors (like sitagliptin) are effective, safe options for lowering blood sugar. GLP-1 agonists offer the added benefit of weight loss, while DPP-4 inhibitors are weight-neutral. Current evidence does not support fears of increased pancreatitis or thyroid cancer risk in humans, making these therapies favorable compared to older drugs that cause weight gain or hypoglycemia.
The benefits by far outweigh the potential risks... Glucagon-like peptide 1 (GLP-1) receptor agonists demonstrate an efficacy comparable to insulin treatment and appear to do so with significant effects to promote weight loss with minimal hypoglycemia... there are significant data with dipeptidyl peptidase 4 (DPP-4) inhibitors showing efficacy comparable to sulfonylureas but with weight neutral effects and reduced risk for hypoglycemia.
Why this rating
Based on extensive clinical trial data, meta-analyses, and long-term human experience, though some long-term cancer risks remain under investigation.
Source
A Critical Analysis of the Clinical Use of Incretin-Based Therapies
Michael A. Nauck · Diabetes Care · 2013
DOI 10.2337/dc12-2504
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →